公开(公告)号：WO2019073062A1

公开(公告)日：2019-04-18

申请号：PCT/EP2018/077953

申请日：2018-10-12

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： RALLABANDI, Bala Ramesha Chary ,  PRATHAP, Vamshi Ramana ,  GOLLAPUDI, Krishna Mohan ,  VELUSAMY, Bala Subramanian ,  BANDLA, Srimannarayana ,  SCHLEHAHN, Hendrik ,  RUCHATZ, Dieter

IPC: A61K9/20 ,  A61K31/225 ,  A61K31/41

CPC classification number: A61K9/2009 ,  A61K9/2095 ,  A61K31/216 ,  A61K31/41 ,  A61K2300/00

Abstract: The present invention relates to a tablet for oral administration containing valsartan and sacubitril, preferably as sodium salts or as a complex of valsartan disodium and sacubitril monosodium, preferably LCZ696. The tablet is prepared by dry-granulation or direct compression and contains a mesoporous inorganic stabilizer, e.g. mesoporous silica (Syloid®).

公开(公告)号：WO2022034232A1

公开(公告)日：2022-02-17

申请号：PCT/EP2021/072649

申请日：2021-08-13

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： PRATHAP, Vamshi Ramana ,  KALAMATA, Venkatasimhadri Naidu ,  MUPKALKER, Ashwini Kumar ,  VELCHURI, Srikanth ,  RALLABANDI, Bala Ramesha Chary ,  MADALLAPALLI, Kiran Kumar ,  SCHLEHAHN, Hendrik ,  FITZNER, Ansgar

IPC: A61K9/14 ,  A61K9/20 ,  A61K31/496

Abstract: The present invention relates to a gastro-resistant high-strength unit dosage form comprising a solid solution prepared by hot-melt extrusion, whereby the solid solution contains 300 mg posaconazole and an enteric polymer in a specific weight ratio. The unit dosage form may be a capsule or optionally film-coated tablet.

公开(公告)号：WO2019097091A1

公开(公告)日：2019-05-23

申请号：PCT/EP2018/085448

申请日：2018-12-18

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： GUJJAR, Chaitanya Yogananda ,  UPPALA, Susheel Prakash ,  DONGA, Nani Prasad ,  BANDLA, Srimannarayana ,  RALLABANDI, Bala Ramesha Chary ,  STAVER, Ruslan ,  SCHLEHAHN, Hendrik

IPC: A61K9/20 ,  A61K31/445 ,  A61P37/08 ,  A61K31/454

Abstract: The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) a crystalline form of bilastine according to crystalline (polymorph) form 3, wherein the crystalline form has characteristic peaks at 6.47, 12.81, 15.70, and 17.71 ± 0.2 degrees 2-theta in a powder X-ray diffraction pattern, b) a water-soluble filler, and optionally c) a water-insoluble filler. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet comprising dry granulation of a blend of the tablet components and compression of the granules to a tablet, or direct compression of a blend to a tablet. The invention relates further to the medical use of the pharmaceutical composition in the treatment of allergic rhino-conjunctivitis and/or urticaria.

公开(公告)号：WO2019097090A1

公开(公告)日：2019-05-23

申请号：PCT/EP2018/085447

申请日：2018-12-18

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： GUJJAR, Chaitanya Yogananda ,  UPPALA, Susheel Prakash ,  DONGA, Nani Prasad ,  BANDLA, Srimannarayana ,  RALLABANDI, Bala Ramesha Chary ,  STAVER, Ruslan ,  SCHLEHAHN, Hendrik

IPC: A61K9/20 ,  A61P37/08 ,  A61K31/454

CPC classification number: A61K9/2009 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/454 ,  A61K33/12 ,  A61P37/08 ,  A61K2300/00

Abstract: The invention relates to a pharmaceutical composition in the form of a tablet, comprising bilastine and magnesium aluminometasilicate. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet comprising dry granulation of a blend of the tablet components and compression of the granules to a tablet, or direct compression of a blend to a tablet. The invention relates further to the medical use of the pharmaceutical composition in the treatment of allergic rhino-conjunctivitis and/or urticaria.

公开(公告)号：WO2023012376A2

公开(公告)日：2023-02-09

申请号：PCT/EP2022/077357

申请日：2022-09-30

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： DÖBBER, Alexander ,  SAGILI, Manohar Reddy ,  GUJJAR, ChaitanyaYogananda ,  KALAMATA, Venkatasimhadri Naidu ,  FITZNER, Ansgar ,  MANKALA, Santhosh Kumar ,  RALLABANDI, Bala Ramesha Chary ,  MADALLAPALLI, Kiran Kumar

IPC: A61K31/55 ,  A61K9/2013 ,  A61K9/2095

Abstract: In the solid pharmaceutical compositions of the present invention, the formation of toxic N-nitroso-derivatives of the contained agents comprising a dialkylamino- or a trialkyl amino-group is prevented providing long-term storage stable formulations- of inherently problematic drugs, such as varenicline (e.g., in form of its tartrate or foe citrate). Means- for achieving the long-term storage stable formulations of the present invention are formulating the crucial active ingredients with antioxidants, using specific packaging materials for the pharmaceutical compositions- of the present invention, and/or employing specific manufacturing processes.

公开(公告)号：WO2019121849A1

公开(公告)日：2019-06-27

申请号：PCT/EP2018/085738

申请日：2018-12-19

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： MUPKALKER, Ashwin Kumar ,  KALAMATA, Venkatasimhadri Naidu ,  RALLABANDI, Bala Ramesha Chary ,  NADELLA, Prasad ,  BANDLA, Srimannarayana ,  STAVER, Ruslan ,  SCHLEHAHN, Hendrik

IPC: A61K9/20 ,  A61P25/18 ,  A61K31/496

Abstract: The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) brexpiprazole as active ingredient and b) at least 5% by weight (wt%) pregelatinized starch (PGS). The invention further relates to methods of preparing a pharmaceutical composition in the form of a tablet, comprising dry granulation of a blend of the components to produce granules and compression of the granules to a tablet. The invention further relates to the use of the composition in the treatment of schizophrenia, major depression, and other central nervous system disorders.

公开(公告)号：WO2019086725A3

公开(公告)日：2019-05-09

申请号：PCT/EP2019/055706

申请日：2019-03-07

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： STAVER, Ruslan ,  PRATHAP, Vamshi Ramana ,  VADLA, Hari Kiran Chary ,  RALLABANDI, Bala Ramesha Chary ,  SCHLEHAHN, Hendrik

IPC: A61K9/20 ,  A61K31/4152 ,  A61P7/02

Abstract: The present invention relates to a pharmaceutical tablet composition comprising eltrombopag olamine, one or more reducing sugars, and one or more polymeric binder agents, a production process therefore, a pharmaceutical tablet composition comprising eltrombopag olamine, one or more reducing sugars, and one or more polymeric binder agents obtainable by the production process, a use / method of use of the pharmaceutical tablet compositions in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe a plastic anaemia (SAA).

公开(公告)号：WO2019086725A2

公开(公告)日：2019-05-09

申请号：PCT/EP2019/055706

申请日：2019-03-07

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： STAVER, Ruslan ,  PRATHAP, Vamshi Ramana ,  VADLA, Hari Kiran Chary ,  RALLABANDI, Bala Ramesha Chary ,  SCHLEHAHN, Hendrik

Abstract: The present invention relates to a pharmaceutical tablet composition comprising eltrombopag olamine, one or more reducing sugars, and one or more polymeric binder agents, a production process therefore, a pharmaceutical tablet composition comprising eltrombopag olamine, one or more reducing sugars, and one or more polymeric binder agents obtainable by the production process, a use / method of use of the pharmaceutical tablet compositions in the treatment or prophylaxis of immune (idiopathic) thrombocytopenic purpura (ITP), thrombocytopenia and/or acquired severe a plastic anaemia (SAA).

公开(公告)号：WO2018178295A1

公开(公告)日：2018-10-04

申请号：PCT/EP2018/058207

申请日：2018-03-29

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： RALLABANDI, Bala Ramesha Chary ,  PRATHAP, Vamshi Ramana ,  GOLLAPUDI, Rajesh Krishna Mohan ,  SCHLEHAHN, Hendrik ,  RUCHATZ, Dieter

IPC: A61K9/14 ,  A61K9/20

CPC classification number: A61K9/146 ,  A61K9/2027 ,  A61K9/2077

Abstract: The present invention relates to a solid unit dosage form for oral administration (tablet or granules) containing a solid dispersion of valsartan and sacubitril in a polymeric matrix. The solid dispersion is prepared by hot-melt extrusion and may contain the active ingredients preferably in a non-crystalline state. LCZ696, (pseudo)polymorphic forms thereof as well as the individual drugs, e.g. valsartan disodium and sacubitril monosodium, may be subjected to the hot-melt extrusion process.

公开(公告)号：WO2020239986A1

公开(公告)日：2020-12-03

申请号：PCT/EP2020/064994

申请日：2020-05-29

Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)

Inventor： RALLABANDI, Bala Ramesha Chary ,  JOSHI, Abhay Ramakant ,  CHAMARTHI, Phanikishore Ravi ,  BANDLA, Srimannarayana ,  PATTIPATI, Srikanth ,  REDDY, Siva Reddy Maram ,  STAVER, Ruslan ,  SCHLEHAHN, Hendrik

IPC: A61K9/20 ,  A61K31/444 ,  A61P7/02

Abstract: The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) edoxaban, or a salt thereof or a hydrate of said edoxaban or edoxaban salt, as an active ingredient, b) lactose as a water-soluble filler, and c) crospovidone and sodium starch glycolate as disintegrants. The invention further relates to the pharmaceutical composition for use as a medicament in the treatment and/or prevention of a medical condition associated with unwanted blood clots, and to methods for preparing the pharmaceutical composition using wet granulation methods.